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Abstract
Background: Lyme neuroborreliosis (LNB), caused by the spirochete Borrelia burgdorferi (Bb), affects both the
central and peripheral nervous systems. Previously, we reported that in a model of acute LNB in rhesus monkeys,
treatment with the anti-inflammatory drug dexamethasone significantly reduced both pleocytosis and levels of
cerebrospinal fluid (CSF) immune mediators that were induced by Bb. Dexamethasone also inhibited the formation
of inflammatory, neurodegenerative, and demyelinating lesions in the brain and spinal cord of these animals. In
contrast, these signs were evident in the infected animals that were left untreated or in those that were treated
with meloxicam, a non-steroidal anti-inflammatory drug.
Methods: To address the differential anti-inflammatory effects of dexamethasone and meloxicam in the central
nervous system (CNS), we evaluated the potential of these drugs to alter the levels of Bb-induced inflammatory
mediators in culture supernatants of rhesus frontal cortex (FC) explants, primary rhesus astrocytes and microglia,
and human oligodendrocytes. We also ascertained the potential of dexamethasone to modulate Bb-induced
apoptosis in rhesus FC explants. As meloxicam is a known COX-2 inhibitor, we evaluated whether meloxicam
altered the levels of COX-2 as induced by live Bb in cell lysates of primary rhesus astrocytes and microglia.
Results: Dexamethasone but not meloxicam significantly reduced the levels of several Bb-induced immune
mediators in culture supernatants of FC explants, astrocytes, microglia, and oligodendrocytes. Dexamethasone also
had a protective effect on Bb-induced neuronal and oligodendrocyte apoptosis in rhesus FC explants. Further,
meloxicam significantly reduced the levels of Bb-induced COX-2 in microglia, while both Bb and meloxicam were
unable to alter the constitutive levels of COX-2 in astrocytes.
Conclusions: These data indicate that dexamethasone and meloxicam have differential anti-inflammatory effects
on Bb-induced inflammation in glial and neuronal cells of the CNS and help explain the in vivo findings of
significantly reduced inflammatory mediators in the CSF and lack of inflammatory neurodegenerative lesions in the
brain and spinal cord of Bb-infected animals that were treated with dexamethasone but not meloxicam. Signaling
cascades altered by dexamethasone could serve as possible therapeutic targets for limiting CNS inflammation and
tissue damage in LNB.
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Background
Lyme disease is caused by infection with the spirochete
Borrelia burgdorferi (Bb) [1]. The nervous system in-
volvement in Lyme disease, called Lyme neuroborreliosis
(LNB), may affect both the central and peripheral ner-
vous systems in about 15% of Lyme disease patients.
Symptoms of acute LNB include painful meningoradicu-
litis with inflammation of dorsal nerve roots and
lancinating, radicular pain (Bannwarth’s syndrome),
lymphocytic meningitis, and various forms of cranial or
peripheral neuritis [2].
The rhesus macaque is the most accurate model of hu-
man LNB [3–6]. Previously, we reported that leptome-
ningitis and radiculitis that manifest in monkeys with
acute LNB are concomitant with the inflammatory
meditator response elicited by Bb [6]. Importantly,
lymphocyte and plasma cell infiltration in the leptomen-
inges and perivascular infiltrates of immune cells adja-
cent to white matter lesions in the brain and transverse
myelitis lesions in the spinal cord have been documented
in pathological examinations of lesions from cases of hu-
man LNB [2, 7, 8].
We hypothesized that Bb induces the production of in-
flammatory mediators in glial and neuronal cells and that
this response has a role in potentiating glial and neuronal
apoptosis. We recently explored if inflammation had a
causal role in mediating the pathogenesis of LNB by
evaluating the inflammatory changes in rhesus macaques
infected with Bb that were left untreated or were given ei-
ther the anti-inflammatory drug dexamethasone, a steroid
that inhibits the expression of several immune mediators
[9], or meloxicam, a non-steroidal anti-inflammatory drug
that inhibits cyclooxygenase-2 (COX-2) [10]. Dexametha-
sone treatment significantly reduced the levels of several
cytokines and chemokines, and pleocytosis in the CSF,
and prevented inflammatory and/or neurodegenerative
and demyelinating lesions in the central and peripheral
nervous systems [11]. Conversely, infected animals that
were treated with meloxicam showed similar levels of im-
mune mediators in the CSF and displayed similar lesions
in the CNS and PNS to those seen in infected animals that
were left untreated. Also, the effects of these drugs in
neuronal cultures of dorsal root ganglia and of myelinat-
ing cells of the PNS infected with Bb showed that dexa-
methasone but not meloxicam significantly reduces the
levels of apoptosis and those of several cytokines and che-
mokines [12].
In this study, we evaluate the effects of these drugs on
Bb-induced inflammation in glial and neuronal cells of
the CNS. Results show that dexamethasone but not
meloxicam significantly reduces the levels of several cy-
tokines and chemokines as induced by live Bb in rhesus
astrocytes, microglia, and FC explants, in addition to hu-
man oligodendrocytes. Likewise, dexamethasone showed
a protective effect on cell death, as both neurons and
oligodendrocytes evinced reduced apoptosis in rhesus
FC explants. Further, meloxicam was able to significantly
reduce the levels of Bb-induced COX-2 in rhesus micro-
glia, while it did not alter the constitutive levels of COX-
2 in rhesus astrocytes. These data indicate that as with
PNS cells [13], dexamethasone and meloxicam have
differential anti-inflammatory effects on Bb-induced in-
flammation in glial and neuronal cells of the CNS.
Methods
Growth and preparation of live spirochetes
B. burgdorferi B31 clone 5A19 spirochetes, passage 1–3,
were grown in Barbour-Stoenner-Kelly (BSK) medium,
supplemented with 6% rabbit serum (Sigma, St. Louis,
MO) and antibiotics (rifampicin at 45.4 μg/mL, phos-
phomycin at 193 μg/mL, and amphotericin at 0.25 μg/
mL) to late logarithmic phase under microaerophilic
conditions. Spirochetes were pelleted, washed using ster-
ile phosphate-buffered saline (PBS), and resuspended in
the working medium at the desired density, as previously
described [12].
Frontal cortex brain (FC) explant experiments: incubation
of brain slices with B. burgdorferi (Bb), dexamethasone,
and meloxicam for collection of culture supernatants for
multiplex ELISA assays and apoptosis assays with tissue
explants
Freshly harvested frontal cortex tissues were collected at
necropsy from three rhesus macaques (Macaca mulatta)
that were scheduled for euthanasia due to chronic idio-
pathic diarrhea or had undergone trauma. Animals were
euthanized in accordance with the recommendations of
the American Veterinary Medical Association’s Panel on
Euthanasia. The frontal cortex was sliced into 2-mm sec-
tions, and each section was placed in separate wells of
12-well plates. Each well contained 2 mL of RPMI 1640
medium (BioWhittaker, Walkersville, MD) supple-
mented with 10% FBS, as previously described [14]. Tis-
sue sections were exposed to medium alone or to
medium with added Bb (1 × 107 bacteria/mL) in the
presence or absence of either 150 μM dexamethasone
(Sigma) or 100 μM meloxicam (Sigma). Controls with
no spirochetes were also included. Prior to stimulation
with live Bb, FC explant cultures were incubated with
the respective concentrations of dexamethasone or
meloxicam for 1 h in a humidified 5% CO2 incubator at
37 °C, after which they were washed and then incubated
in fresh growth medium containing the appropriate con-
centrations of dexamethasone or meloxicam and live Bb
for an additional 6 h at 37 °C. The above concentrations
of dexamethasone and meloxicam were the highest con-
centrations that were found to be safe as evaluated by
the trypan blue exclusion assay (Sigma) in previous
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studies with cultures of human Schwann cells and rhe-
sus dorsal root ganglia cultures [13]. At the end of the
incubation times, culture supernatants were collected
for evaluation of inflammatory mediators. Culture super-
natants were centrifuged at 4 °C at 2000 × g to remove
any suspended bacteria, and the supernatant was ali-
quoted and stored at −70 °C until used, as previously re-
ported [13]. Tissue explants in respective wells were
fixed using 2% paraformaldehyde and cryopreserved for
apoptosis assays.
Primary cultures of rhesus astrocytes and microglia
Primary rhesus astrocyte and microglial cultures were
established following previously described protocols
[15]. Briefly, after the meninges and blood vessels from
fresh frontal cortex tissue were removed, tissue was
mechanically dissociated, treated with 0.25% trypsin,
0.38 g/mL EDTA (Invitrogen), and 0.1% DNase (Sigma-
Aldrich), and incubated at 37 °C for 40 min with inter-
mittent shaking. After incubation, the dissociated tissue
was centrifuged for 10 min at 425 × g and cells filtered
through a Nitex filter (20 μm) and resuspended in glial
culture medium, which was composed of DMEM-F-12
with L-glutamine and HEPES buffer, 10% fetal bovine
serum (HyClone), 0.5 ng/mL of granulocyte-macrophage
colony-stimulating factor (Sigma-Aldrich), 100 U/mL
penicillin, and 100 μg/mL streptomycin. After 14 to
21 days in culture at 37 °C, dislodged microglia were
collected after vigorously tapping the flasks, and resus-
pended in glial culture medium.
To obtain purified astrocytes, glial cells were incubated
for 90 min in 10 mM L-leucine methyl ester (LME)
(Sigma-Aldrich). This concentration has been shown to
be effective in ensuring maximal microglial lysis with
minimal toxicity to astrocytes [15]. Thereafter, astrocytes
were washed thoroughly and resuspended in glial culture
medium. Purity of astrocytes and microglial cultures was
assessed by staining with a specific microglial marker
anti-IBA antibody at a concentration of 1:50 (Wako
Chemicals, Richmond, VA) and was routinely of 99%.
Astrocyte cultures were stained with astroglial marker
anti-GFAP antibody at a dilution of 1:200 (Sigma) after
permeabilizing fixed astrocyte cultures with a mixture of
chilled ethanol-acetic acid mixture (2:1), for 5 min at
−20 °C, for detection of intracellular phenotypic markers
as previously described [16]. Confocal microscopy was
performed using a Leica TCS SP8 confocal microscope
(Leica Microsystems, Exton, PA).
Human oligodendrocyte cultures
The human oligodendrocyte cell line MO3.13 obtained
from CELLutions Biosystems Inc. (Burlington, Ontario,
Canada) was revived and established following ma-
nufacturer’s instructions as previously described [17].
Differentiated oligodendrocytes were obtained after
maintaining cultures in differentiation medium (DM),
consisting of DMEM, P/S, and phorbol 12-myristate
13-acetate (Sigma), at a concentration of 100 nM and
devoid of serum.
Evaluating the anti-inflammatory potential of
dexamethasone and meloxicam in rhesus astrocytes and
microglia and human oligodendrocyte cultures stimulated
with live Bb
Glial and Bb cultures were washed in their respective
media, devoid of antibiotics. Controls with no spirochetes
were also included. Prior to stimulation with live Bb, glial
cell cultures were incubated with various concentrations of
dexamethasone 5 μM, 15 μM and 150 μM (Sigma) or
meloxicam 1 μM, 10 μM, 50 μM and 100 μM (Sigma) for
2 h at 37 °C, after which they were washed and then incu-
bated in fresh growth medium containing the respective
concentrations of dexamethasone or meloxicam and live
Bb at a multiplicity of infection (MOI) of 10:1 at 37 °C. The
effect of the carrier substance of dexamethasone (2-hy-
droxypropyl)-β-cyclodextrin), at the respective molar con-
centrations accompanying dexamethasone, was assessed by
incubating rhesus astrocytes and microglial cultures in the
presence and absence of Bb and carrier alone at 15, 45, and
450 μM, respectively, as previously described for oligo-
dendrocyte cultures [16]. After 48 h, culture supernatants
were collected and processed for evaluation of inflamma-
tory mediators. The drug concentrations were chosen based
on previous reports where dexamethasone (5–150 μM) had
been shown to inhibit the production of CCL2 in mice
microglia [18], and meloxicam (1–100 μM) had been
shown to be effective in inhibiting COX-2 in vitro [19].
Evaluation of immune mediators from culture supernatants
The concentrations of cytokines and chemokines present
in the culture supernatants from rhesus astrocyte and
microglial cultures and rhesus FC explant cultures were
quantified using the MilliPlex MAP Non-Human Primate
Cytokine Magnetic Bead Panel-Premixed 23 Plex,
Cytokine-Chemokine Array kit (Millipore), following the
manufacturer’s instructions. The concentrations of cyto-
kines and chemokines present in the culture supernatants
from human oligodendrocytes were quantified using the
Human 14-plex Cytokine-Chemokine Array kit (Milli-
pore), following the manufacturer’s instructions. The
multiplex plate was read using a Bio-Plex 200 Suspension
Array Luminex System (Bio-Rad, Hercules, CA, USA).
Apoptosis by in situ TUNEL assay and confocal microscopy
Tissue sections from rhesus FC explants were incubated
with anti-NeuN or anti-S-100 antibodies and then sub-
jected to the TUNEL-ApopTagPlus fluorescein in situ
apoptosis assay (Chemicon, Temecula, CA) as previously
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described [14]. The percentage of apoptotic neurons and
the percentage of apoptotic oligodendrocytes in brain
sections were evaluated by counting at least 500 cells,
followed by the percentage of cells that showed co-
localization of both the terminal deoxynucleotidyl trans-
ferase dUTP nick end labeling (TUNEL) signal and
NeuN or S-100 expression, respectively. Apoptotic cells
from ten fields were counted from each section for the
various incubation conditions. All counts were made by
viewing slides under a fixed magnification of ×63 (corre-
sponding to an area of 0.05 mm2) using the Leica TCS
SP8 confocal microscope. The identity of the oligodendro-
cytes that stained with the anti-S-100 antibody was con-
firmed by their morphology as previously described [14].
COX-2 activity assay from culture lysates
Astrocytes and microglia cell lysates were prepared fol-
lowing the manufacturer’s instructions described in the
COX Activity Assay Kit (Cayman Chemicals, Ann Arbor,
MI). The Cayman’s COX activity assay kit measures the
total peroxidase activity of COX in cell lysates and is
assayed colorimetrically by monitoring the appearance
of oxidized N, N, N′,N′-tetramethyl-p-phenylenedi-
amine (TMPD) at 590 nm. The total COX-2 activity in
the sample was calculated using the formula provided by
the manufacturer.
Statistical evaluation
The two-way ANOVA and Tukey’s multiple comparison
test was used to evaluate the statistical significance be-
tween means of data sets, using Graphpad Prism soft-
ware (Graph Pad Software Inc.) version 5.
Results
Effects of dexamethasone and meloxicam on the levels of
cytokines and chemokines induced by Bb in rhesus
frontal cortex explants
Culture supernatants from slices of the frontal cortex
that were incubated with Bb and treated with dexa-
methasone resulted in significantly reduced levels of IL-
6, IL-8, CCL2, IL-1β, IL-18, TNF-α, VEGF, and G-CSF,
compared with slices that were incubated with Bb alone.
In contrast, results from meloxicam treatment showed
that this non-steroidal drug was unable to significantly
reduce the levels of the pro-inflammatory cytokines and
chemokines evaluated (Fig. 1a–i). The levels of IL-10, a
cytokine known to counteract pro-inflammatory media-
tors, were also measured, and results showed that there
were no significant differences after treatment with ei-
ther one of the anti-inflammatory drugs (Fig. 1e). How-
ever, the level of IL-10 was lower after dexamethasone
treatment than it was with Bb alone, albeit not signifi-
cantly. The pattern of mediator response found in the
tissue section supernatants was also present in the tissue
lysates (data not shown).
Effects of dexamethasone and meloxicam on the levels of
CCL2 induced by Bb in cultures of rhesus astrocytes and
microglia and human oligodendrocytes
A mediator predominantly released by microglia in vitro
and into the CSF of rhesus macaques with Lyme meningi-
tis is the chemokine CCL2 [16, 20]. Therefore, we
evaluated the ability of different concentrations of dexa-
methasone and meloxicam to reduce CCL2 levels induced
by Bb in cultures of primary rhesus astrocytes and micro-
glia, as well as human oligodendrocytes after 48 h of incu-
bation. As expected, dexamethasone (Fig. 2b, e, h) but not
meloxicam (Fig. 2c, f, i) significantly reduced CCL2 levels
at the drug concentrations tested. Moreover, the anti-
inflammatory effect of the dexamethasone formulation
was confirmed to be due to its dexamethasone fraction
and not due to the carrier substance (2-hydroxypropyl)-β-
cyclodextrin (HPC) (Fig. 2b, e, h).
The effect of these two anti-inflammatory drugs was
also assessed using a multiplex analysis of cytokines and
chemokines that were released from the studied glial
cells in the presence of Bb. Table 1 summarizes these re-
sults and shows that multiple mediators are significantly
affected by dexamethasone but not by meloxicam.
Dexamethasone protects FC neurons and
oligodendrocytes from Bb-induced apoptosis
Live Bb induced enhanced levels of apoptosis, as mea-
sured by the TUNEL assay, in both neurons and oligoden-
drocytes as compared to medium alone. A representative
confocal image of apoptosis in the presence of live Bb, as
visualized by the in situ TUNEL assay, and a graph of the
quantification levels of dexamethasone protection in neu-
rons are shown in Fig. 3a, b and in oligodendrocytes in
Fig. 3c, d.
Meloxicam affects levels of COX-2 induced by Bb in in
vitro cultures of rhesus microglia but not of astrocytes
COX-2 is known to be involved in both inflammation
and apoptosis in brain disorders [21]. As meloxicam is a
known COX-2 inhibitor, we evaluated whether it was
capable of altering the levels of COX-2 induced by live
Bb in cell lysates of rhesus astrocytes and microglia. Re-
sults showed that at a concentration within the range
used in our assays, this non-steroidal anti-inflammatory
drug had an effect in microglia but not in astrocytes
(Fig. 4). However, COX-2 appears to be constitutively
expressed in astrocytes (Fig. 4b). Thus, meloxicam sig-
nificantly reduced COX-2 levels as induced by Bb in rhe-
sus microglia (Fig. 4a) but was unable to reduce the
levels of pro-inflammatory cytokines and chemokines
(Fig. 2c, f, i). These results suggest a cell type differential
Ramesh et al. Journal of Neuroinflammation  (2017) 14:28 Page 4 of 10
expression of COX-2 and demonstrate that meloxicam
is able to exert its effects in specific cell targets where
COX-2 levels are upregulated by Bb.
Discussion
Once inside the CNS, Bb spirochetes elicit inflammatory
mediators from glial and neuronal cells, as well as lym-
phomonocytic pleocytosis in the CSF [11, 12, 16, 22, 23].
Research models have allowed insights into the patho-
genesis of LNB, and although several studies suggest that
inflammation is required to trigger apoptosis of neurons
and glial cells, a causal relationship between these two
phenomena had not been demonstrated. Recently, we
addressed the hypothesis that inflammation is a key fac-
tor in LNB pathogenesis by using two well-known anti-
inflammatory drugs, dexamethasone and meloxicam, in
a rhesus macaque model. Results revealed that dexa-
methasone but not meloxicam treatment effectively sup-
pressed inflammation due to exposure to Bb, and this
resulted in inhibition of glial and neuronal damage [11].
To corroborate this finding, our in vitro studies using
PNS cells, namely, primary DRG neurons and human
Schwann cell cultures also explored the effects of such
drugs in the presence of Bb [13]. Dexamethasone and
Fig. 1 Dexamethasone but not meloxicam reduces the levels of Bb-induced cytokines and chemokines in frontal cortex explants after 6 h of
incubation. The graphs represent the effect of the anti-inflammatory drugs on the levels of a IL-6, b IL-8, c CCL2, d IL-1β, e IL-10, f IL-18, g TNF-α,
h VEGF, and i G-CSF. The two-way ANOVA and Tukey’s multiple comparison test were used to evaluate the statistical significance between means
and SEM of triplicate data sets, *p < 0.05, **p < 0.01, ***p < 0.001
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meloxicam demonstrated to have differential anti-
inflammatory effects, with dexamethasone being the
only one able to significantly reduce Bb-induced im-
mune mediators and apoptosis of PNS cells.
Here, we assessed the ability of dexamethasone and
meloxicam to affect inflammation and apoptosis in CNS
cells and tissues. To this end, we evaluated the levels of
Bb-induced inflammatory mediators in culture superna-
tants of rhesus FC explants (Fig. 1) and purified primary
rhesus astrocytes and microglia and human oligodendro-
cytes (Fig. 2). We also ascertained the potential of dexa-
methasone to modulate Bb-induced neuronal and
oligodendrocyte apoptosis in rhesus FC explants (Fig. 3).
The compiled results from this study help to explain our
in vivo findings of significantly reduced inflammatory
mediators in the CSF and lack of inflammatory neu-
rodegenerative lesions in the brain and spinal cord of
Bb-infected animals that were treated with dexa-
methasone [11].
The Bb genome encodes, approximately, 150 lipopro-
teins that play an important role in disease pathogenesis
and host immunity [24]. The majority of the pro-
inflammatory lipoproteins are outer surface proteins,
and their differential expression in various tissues and at
different times during infection appear to be critical de-
terminants of disease [17, 25]. An effective host response
Fig. 2 Dexamethasone but not meloxicam affects the levels of CCL2 induced by live Bb at a multiplicity of infection of 10:1 in in vitro cultures of
rhesus astrocytes (a–c), rhesus microglia (d–f), and human oligodendrocytes (g–i) after 48 h of incubation. The effect of different concentrations
of dexamethasone (b, e, h) and meloxicam (c, f, i) on the levels of CCL2 as induced by live Bb in different glial cells are represented in the graphs.
Representative confocal micrographs showing cell morphology and cell culture purity of a primary rhesus astrocytes (GFAP, red), b primary rhesus
microglia (IBA-1, green), and c human oligodendrocytes (MBP, green). The nuclei of all cells in a–c appear blue due to staining with the nuclear stain
TOPRO3. The two-way ANOVA and Tukey’s multiple comparison test were used to evaluate the statistical significance between means and SEM of
triplicate data sets for astrocytes and microglia, and the mean and SD from two assessments of human oligodendrocytes, ***p < 0.001
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will contain or clear infections. However, if this re-
sponse is continually activated, it may lead to lesion
development and disease. It is still a matter of debate
how spirochetes pass the blood–brain barrier, but
hematogenous dissemination appears to be a suitable
way [2]. Once they enter the CNS, Bb encounter im-
mune cells such as monocytes, macrophages, or den-
dritic cells, as well as glial cells such as microglia and
astrocytes, all of which produce pro-inflammatory cy-
tokines, e.g., IL-6, IL-8, IL-12, IL-18, and IFNγ, and
Table 1 Cytokines and chemokines are induced by Bb in glial cells of the CNS and significantly reduced by dexamethasone (when
used at concentrations of 150 μM; p < 0.001), as evaluated in culture supernatants after 48 h. Meloxicam had no effect
Rhesus astrocytes Rhesus microglia Human oligodendrocytes
Mediator pg/mL Bb Bb + dex Mediator pg/mL Bb Bb + dex Mediator pg/mL Bb Bb + dex
IL-1β 24 0 IL-1β 64 ± 10 0 IL-6 141 ± 1.2 65 ± 2.7
IL-2 146 21.8 ± 10 IL-2 268 ± 12 54 IL-8 1145 ± 609 97 ± 2.2
IL-6 27175 ± 2567 596 ± 51 IL-6 92562 ± 2979 1319 ± 77 CCL2 5691 ± 410 1898 ± 96
IL-8 113486 ± 882 1636 ± 40 IL-8 493804 ± 3550 3069 ± 309
IL-10 36 3.72 IL-10 40.45 ± 6.26 17.94
CCL2 76594 ± 1076 2442 ± 260 CCL2 256397 ± 2581 12415 ± 409
CCL3 95.43 0 CCL3 2948 ± 176 136 ± 10
CCL4 25.34 0 CCL4 183.64 0
VEGF 1220 ± 122 0 VEGF 3153 ± 108 941 ± 28
GMCSF 674 ± 20 0 GMCSF 3076 ± 127 501 ± 6.14
TNF-α 569 ± 45 0
Fig. 3 Dexamethasone protects FC neurons (a, b) and oligodendrocytes (c, d) from Bb-induced apoptosis. Representative images of apoptosis
after immunofluorescence staining and visualized by confocal microscopy by the in situ TUNEL assay (green) in a neurons stained with NeuN
(red), and c oligodendrocytes stained with S-100 (red). b, d Graphical representations of the effect of dexamethasone on the levels of apoptosis in
neurons and oligodendrocytes, respectively, as induced by live Bb. The two-way ANOVA and Tukey’s multiple comparison test were used to
evaluate the statistical significance between means and SD of ten data sets (approximately 500 cells) for each condition, **p < 0.01, ***p < 0.001
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chemokines such as I-TAC, CCL2, CXCL-11, and
CXCL13, as found in the CSF of patients [26–30] and
rhesus macaques with LNB [11, 14]. In this study, we
have demonstrated, with CNS cells and tissues, that a
continuous inflammatory response is detrimental and
leads to neural cell death.
Previously, we have shown that meloxicam was not a
viable adjunctive therapeutic agent for the treatment of
Bb-induced inflammation [11, 13]. Our present ex vivo
and in vitro experiments (Fig. 1 and Table 1) confirm
this finding. Meloxicam is analgesic and antipyretic; has
a high gastric and renal tolerance; a high therapeutic
index; and preferentially inhibits COX-2 [31]. To con-
firm that meloxicam effectively acted as a COX-2 inhibi-
tor at the concentrations used in our study, we
evaluated if this drug could dampen the level of this en-
zyme, as induced by live Bb in cell lysates of primary
rhesus astrocytes and microglia. As shown in Fig. 4,
meloxicam significantly reduced COX-2 levels from Bb-
infected microglia (Fig. 4a), while it was unable to alter
the constitutive levels of COX-2 in astrocytes (Fig. 4b).
This verifies, on the one hand, that COX-2 is not caus-
ally involved in the inflammation by microglia in re-
sponse to Bb, as indicated by the lack of microglial anti-
inflammatory response to meloxicam, and on the other,
that astrocytes do not respond to Bb by elevating the ex-
pression of COX-2.
Antibiotics will continue to be the first-line therapy
for Lyme borreliosis. Steroids have been administered
alongside antibiotics, with the literature reporting some
beneficial effects [32, 33]. However, opposite results have
been obtained as well in cases of facial palsy associated
with Lyme neuroborreliosis [34]. Thus far, the findings
from our group included in vivo, ex vivo, and in vitro
works that used different neuronal and glial cells and
suggested a protective role of dexamethasone in LNB.
However, the implications of dexamethasone with regard
to the treatment of human disease are not clear. What is
known is that dexamethasone interferes with pro-
inflammatory signal transduction, gene expression, and
protein synthesis at various levels [35, 36]. The actions
of dexamethasone in bacterially induced TLR-mediated
pro-inflammatory signaling involve inhibition of IκBα
phosphorylation and degradation as well as NF-κB
DNA-binding activity [35]. Moreover, MEK, JNK, and
p38, all belonging to the family of MAPKs, are promin-
ent targets of dexamethasone [37–40]. A recent study
from our group showed that the TLR2 pathway plays a
predominant role in inducing CNS cell inflammation in
response to Bb and that the downstream signaling
involves the MyD88 and MAPK pathways [41]. Accord-
ingly, it is possible that dexamethasone inhibits Bb-
induced TLR2 signaling and the MEK/ERK pathway,
reducing inflammation and subsequent apoptosis. Over-
all, our data suggest that inflammation has a causal
role in the pathogenesis of CNS LNB. Further evalu-
ation of its signaling and immunomodulatory mecha-
nisms is still required to ascertain which inhibitors of
inflammation may be safely used to mitigate the signs
and symptoms of LNB.
Conclusions
These results indicate that dexamethasone and meloxi-
cam have differential anti-inflammatory effects on Bb-
induced inflammation in glial and neuronal cells of the
CNS and help explain the in vivo findings of significantly
reduced inflammatory mediators in the CSF and lack of
inflammatory neurodegenerative lesions in the brain and
spinal cord of Bb-infected animals that were treated with
dexamethasone but not meloxicam. Signaling cascades
altered by dexamethasone could serve as possible thera-
peutic targets for limiting CNS inflammation and tissue
damage in LNB.
Fig. 4 Meloxicam’s effect on COX-2 levels induced by live Bb in rhesus: a microglia and b astrocytes after 24 h of incubation. The two-way
ANOVA and Tukey’s multiple comparison test were used to evaluate the statistical significance between means and SEM of triplicate data sets for
microglia and astrocytes, **p < 0.01
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